Detalhe da pesquisa
1.
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Oncotarget
; 11(14): 1289, 2020 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292577
2.
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Mol Cancer Ther
; 18(12): 2368-2380, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439712
3.
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Oncotarget
; 9(81): 35226-35240, 2018 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30443290
4.
Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
ACS Med Chem Lett
; 3(6): 445-9, 2012 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900493
5.
4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
J Med Chem
; 53(22): 7938-57, 2010 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-21038853